100. výročí založení AATS

Jan Harrer

Interv Akut Kardiol. 2017;16(3):95-96  

Antiplatelet therapy after BVS implantation

Martin Malý

Interv Akut Kardiol. 2017;16(3):103-105 | DOI: 10.36290/kar.2017.018  

It is not possible to simply adopt the guidelines’ for the length of dual antiplatelet therapy after metal stent implantation andapply them for the bioresorbable scaffold implantation. It is due to the differences in the technology and also the mechanicalproperties of scaffolds are changing during the process of resorption. In this report we focus on the interpretation of the limiteddata from the trials and we will try to formulate the recommendation for the antiplatelet treatment after the scaffold implantation.

Bioresorbable vascular scaffold – good idea worth further effort

Viktor Kočka

Interv Akut Kardiol. 2017;16(3):106-108 | DOI: 10.36290/kar.2017.019  

Currently, absorbable stents should not be used in routine clinical practice since their safety has been questioned. This fact, however,should not stand in the way of further development of this intuitively correct concept since long-term data after implantation ofpermanent metal stents show a constantly increasing incidence of clinical events. In the future, a better technique of implantationof absorbable stents can be expected and technological progress is also very promising. The author summarizes several potentialadvantages of the absence of a permanent foreign body in a coronary artery. The routine use of absorbable stents can be consideredin...

Biodegradable stents: an uncertain future

Michael Želízko

Interv Akut Kardiol. 2017;16(3):110-112 | DOI: 10.36290/kar.2017.020  

The introduction of coronary stents in 1986 change the practice of interventional cardiology since its inception in 1977. Furtherdevelopment lead to metallic drug eluting stents (DES) with improving mechanical properties, decreasing strut thickness and introducingdegradable polymer or nonpolymer, abluminal drug coating. Leaving metallic support lifelong have generated interesttowards biodegradable technology. These temporary biodegradable vascular supports, made of polymers or metal alloys with a drugcoating, have the potential to scaffold the artery to allow natural healing, and then biodegrade. The development of this technologyhas been slow, several...

Very late thrombosis in bioresorbable scaffold

Juraj Bujdák, Ivo Varvařovský, Vojtěch Novotný, Jan Matějka

Interv Akut Kardiol. 2017;16(3):113-115 | DOI: 10.36290/kar.2017.031  

The authors report a case of very late thrombosis in a patient with a bioresorbable scaffold. In the discussion are considered possibleetiological factors of this event, the results of clinical trials and current recommendations for long-term antiplatelet therapy.

The future of bioresorbable stents

Ivo Varvařovský

Interv Akut Kardiol. 2017;16(3):116-118 | DOI: 10.36290/kar.2017.032  

Review of the current development in the field of bioresorbable stents.

Clinical outcome of patients treated with Absorb BVS: a single centre experience

Vojtěch Novotný, Milan Plíva, Tomáš Lazarák, Ivo Varvařovský, Jan Matějka, Vladimír Rozsíval, Petr Vojtíšek

Interv Akut Kardiol. 2017;16(3):98-102 | DOI: 10.36290/kar.2017.030  

Aim: Absorb BVS™ (Abbott Vascular, Santa Monica, CA, USA) is the longest clinically available biodegradable stent (bioresorbablevascular scaffold, BVS). Despite promising results, pitfalls associated with treatment with this type of coronary implants haveemerged. This were the registries at first, some meta-analyses subsequently, the three-year results of the ABSORB II randomizedtrial in autumn 2016 that suggested an increased risk of thrombosis of the BVS stent compared with the newest-generation DES.The aim of our study was to evaluate the clinical outcomes of a real population of patients with implanted BVS with an emphasison the incidence...

Hemodynamically insignificant but high-risk morphology left main stenosis.
Revascularization or conservative therapy?

Tomáš Kovárník, Jan Bělohlávek

Interv Akut Kardiol. 2017;16(3):120-122 | DOI: 10.36290/kar.2017.017  

Authors present a case of unstable plaque located in the left main coronary artery that has been treated by a stent implantationdespite it’s hemodynamic non-significance. Furthermore, it is discussed a summary of known recommendation for percutaneousintervention of not-flow limiting stenoses.

Acute pulmonary embolism in a patient with aortic dissection of unknown date

Nikoleta Filyóová, Karel Lábr, Vladimír Kincl, Jiří Seménka, Marta Pažourková, Olga Pokorná

Interv Akut Kardiol. 2017;16(3):124-127 | DOI: 10.36290/kar.2017.016  

Pulmonary embolism is a relatively common disease. The case report of simultaneous pulmonary embolism and aortic dissectionis presented. Although the pulmonary embolism is more frequently treated non-invasively (anticoagulants or thrombolysis), inour patient a surgical treatment was chosen because of the extent of the emboli. A massive pulmonary embolism that occludedthe pulmonary artery bilaterally was described on pulmonary angiography. The aortic dissection type B is often managed withusing endovascular treatment, but in this case a conservative approach was chosen because the dissection very probably wasn´ta new condition. The dissection was diagnosed...

Kongres Evropské kardiologické společnosti Barcelona 2017

František Holm

Interv Akut Kardiol. 2017;16(3):129-130  

Prof. MUDr. Jan Vojáček, DrSc., FESC, FACC – sedmdesátiletý

MUDr. Josef Bis, Ph.D.

Interv Akut Kardiol. 2017;16(3):131-132